DESCRIPTION
A 37-year-old man presented with generalised bony pains and severe progressive lower limb proximal weakness of 2 years duration. There was no preceding history of fever, morning stiffness, muscle pain, joint swellings, fractures, skin rashes, photosensitivity, diarrhoeal illness or taking long-term medications for any systemic conditions. There was no significant family history. Examination was unremarkable except for severe lower limb proximal muscle weakness and bony tenderness.
His biochemical evaluation was as followsserum phosphorus: 1. figure 1A, B) . He underwent complete excision biopsy of the above lesion which was characteristic of phosphaturic mesenchymal tumour (figure 2) suggesting a diagnosis of oncogenic osteomalacia. On follow-up at 2 months, he made remarkable recovery and his serum phosphorus and FGF23 levels were within normal limits.
Oncogenic osteomalacia, is an uncommon paraneoplastic syndrome characterised by severe hypophosphataemia secondary to mesenchymal tumours secreting phosphotonins like FGF23. Usually they are located in the head and neck region. 1 The GA DOTATATE PET/CT study is the investigation of the choice for the localisation. Once these tumours are completely excised, most of the patients improve significantly and remain symptom free. 2 Learning points ▸ Oncogenic osteomalacia (otherwise known as tumour-induced osteomalacia) is a rare cause of hypophosphataemic osteomalacia secondary to mesenchymal tumours. ▸ Most of these tumours are usually located in the head and neck region which secrete phosphotonins (eg, phosphaturic factors) like fibroblast growth factor 23 causing renal phosphate loss and osteomalacia. ▸ The GA DOTATATE PET/CT study is the investigation of the choice for the localisation.
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